Keywords: Glucagon-like peptide 1 receptor agonists, inflammation, inflammatory bowel disease, neurodegenerative disorder, nuclear factor-kappa B, obesity, type-2 diabetes.
The GLP-1 RAs could be an effective option for obesity management in IBD. However, the robustness of the current study's results is limited by potential bias in the included studies and small sample sizes in the secondary outcomes analysis.
This months issue of Gastroenterology & Hepatology examines the use of these agents specifically in patients who have inflammatory bowel disease (IBD). In our Advances in IBD column, Dr Christine Boumitri critiques the research available thus far on the use of GLP-1 receptor agonists...
GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use.
Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 Receptor Agonists For Inflammatory Bowel Disease.
GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.Association of GLP-1 receptor agonists with chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes.
GLP-1 receptor agonists are highly effective medicines for treating diabetes and obesity, helping patients lower blood sugar, lose weight, and improve heart and kidney health.
GLP-1 receptor agonists have emerged as biologically plausible modulators of reward circuitry and addictive behavior. Preclinical data are robust and consistent across substances, while human evidence provides encouraging but non-causal signals.
Glucagon-like peptide 1 (GLP-1) receptor agonists, widely used to treat diabetes and obesity, may offer a lifeline for inflammatory bowel disease (IBD) patients suffering from short gut syndrome, according to an abstract presented at the Advances in Inflammatory Bowel Diseases...
The Science Behind GLP-1 Receptor Agonists. As I reflected on my experience, I wondered if others had noticed similar benefits.(2022). GLP-1 receptor agonists in inflammatory bowel disease: A new therapeutic approach.
